PF-05231023 intravenous doses evaluated for preliminary safety and tolerability in Type 2 Diabetes
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
Background
Type 2 Diabetes Mellitus (T2DM) remains a significant global health challenge, characterized by insulin resistance and progressive beta-cell dysfunction. Despite numerous available therapies, many patients struggle to achieve optimal glycemic control, and long-term complications like cardiovascular disease, neuropathy, and nephropathy persist. There is a continuous need for novel therapeutic agents that offer improved efficacy, better safety profiles, or unique mechanisms of action to address the diverse pathophysiology of T2DM and prevent its debilitating consequences. Investigating new compounds like PF-05231023 in early-stage trials is crucial for identifying potential future treatments.